Please use this identifier to cite or link to this item: http://hdl.handle.net/1843/61743
Type: Artigo de Periódico
Title: The International Vitreoretinal B-Cell Lymphoma Registry: a protocol paper
Authors: Justine R. Smith
Valérie Touitou
Daniel Vítor de Vasconcelos Santos
David J. Wilson
Steven Yeh
Mark H. B. Radford
Alexandra L. Farrall
Janet L. Davis
Joke H. de Boer
Anthony J. Hall
Manabu Mochizuki
H. Nida Sen
Hiroshi Takase
Ninette H. Ten Dam-van Loon
Abstract: Introduction Vitreoretinal lymphoma is a rare ocular cancer with high morbidity and mortality despite treatment. Diagnosis by cytopathology is often delayed, and various molecular and image-based investigations have been developed. Diverse treatments are used, but there is a limited medical evidence to differentiate their effectiveness. We designed an international registry that would collect diagnostic, treatment and outcomes data, to establish new evidence for the management of this cancer. Methods and analysis The International Vitreoretinal B-Cell Lymphoma Registry will accrue data retrospectively for individuals aged 18 years or older, diagnosed with new or recurrent vitreoretinal B-cell lymphoma on or after 1 January 2020. A steering committee of subspecialised ophthalmologists identified 20 key clinical data items that describe patient demographics, tissue involvements, diagnostic testing, ocular and systemic treatments and treatment complications, and visual acuity and survival outcomes. Customised software was designed to permit collection of these data across a single baseline and multiple follow-up forms. The platform collects data without identifiers and at 3 month reporting intervals. Outcomes of the project will include: (1) descriptions of clinical presentations, and diagnostic and therapeutic preferences; (2) associations between clinical presentations, and diagnostics and treatments, and between diagnostics and treatments (assessed by ORs with 95% CIs); and (3) estimations of rates of vision loss, and progression-free and overall survival (assessed by Kaplan-Meier estimates). Ethics and dissemination The registry has received Australia-wide approval by a national human research ethics committee. Sites located outside Australia are required to seek local human research ethics review. Results generated through the registry will be disseminated primarily by peer-reviewed publications that are expected to inform clinical practice, as well as educational materials.
Subject: Guias como Assunto
Linfoma
Neoplasias
language: eng
metadata.dc.publisher.country: Brasil
Publisher: Universidade Federal de Minas Gerais
Publisher Initials: UFMG
metadata.dc.publisher.department: MED - DEPARTAMENTO DE OFTALMOLOGIA E OTORRINOLARINGOLOGIA
MEDICINA - FACULDADE DE MEDICINA
Rights: Acesso Aberto
metadata.dc.identifier.doi: https://doi.org/10.1136/bmjopen-2021-060701
URI: http://hdl.handle.net/1843/61743
Issue Date: 2022
metadata.dc.url.externa: https://bmjopen.bmj.com/content/12/7/e060701
metadata.dc.relation.ispartof: BMJ Open
Appears in Collections:Artigo de Periódico

Files in This Item:
File Description SizeFormat 
The International Vitreoretinal B-Cell Lymphoma Registry_ a protocol paper.pdf161.63 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.